Related Experiment Video
Updated: Sep 13, 2025
07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
318
Extracorporeal Cytokine Adsorption in Sepsis: Current Evidence and Future Perspectives
Matteo Guarino1,2, Anna Costanzini1, Francesco Luppi1
1Department of Translational Medicine, St. Anna University Hospital of Ferrara, University of Ferrara, 44124 Ferrara, Italy.
Biomedicines
|July 29, 2025
Summary
Extracorporeal cytokine adsorption shows promise in managing sepsis by reducing inflammation and improving organ function. However, its impact on reducing mortality in sepsis patients requires further investigation through large clinical trials.
Area of Science:
- Critical Care Medicine
- Immunology
- Nephrology
Background:
- Sepsis and septic shock are leading causes of death globally.
- The "cytokine storm" is a key factor in sepsis, causing organ failure.
- Extracorporporeal cytokine adsorption therapies aim to reduce inflammatory mediators.
Purpose of the Study:
- To evaluate the efficacy and safety of extracorporeal cytokine adsorption therapies in sepsis.
- To assess the impact of these therapies on inflammatory markers and organ function.
- To review current evidence on mortality reduction associated with these treatments.
Main Methods:
- Comprehensive literature search of Scopus and PubMed (Jan 2020 - May 2025).
- Inclusion of clinical trials and meta-analyses on sepsis and extracorporeal cytokine adsorption.
- Analysis of studies focusing on efficacy, safety, and clinical outcomes.
Main Results:
- Therapies show potential in lowering cytokine levels and improving organ function.
- Reduced vasopressor needs observed in some patient populations.
- Inconsistent evidence regarding significant mortality reduction in sepsis.
- Benefits noted in sepsis, ARDS, and cardiogenic shock.
Conclusions:
- Extracorporeal cytokine adsorption is a potential adjunctive therapy for sepsis management.
- Improvements in organ function and inflammatory control are key benefits.
- Further large-scale trials are needed to confirm mortality benefits and optimize use.
